vTv Therapeutics
VTVT
41 hedge funds and large institutions have $20M invested in vTv Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 8 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
12.89% more ownership
Funds ownership: 37.92% → 50.81% (+13%)
7% less funds holding
Funds holding: 44 → 41 (-3)
9% less capital invested
Capital invested by funds: $22.1M → $20M (-$2.05M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
+$5.75M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.81M |
| 3 |
RA
Royce & Associates
New York
|
+$845K |
| 4 |
JP Morgan Chase
New York
|
+$719K |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$599K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.04M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$827K |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$541K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$267K |
| 5 |
Renaissance Technologies
New York
|
-$215K |
VTVT Hedge Fund Activity: Q1 2018 in Review
41 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2018, worth a combined $20M — down 9.3% from $22.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VTVT and 5 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 13 added.
The largest buyer was GMT Capital, opening a new position worth an estimated $5.75M. The largest seller was Ameriprise, exiting entirely with an estimated $1.04M sold.
- 41 institutional investors held vTv Therapeutics (VTVT) as of Q1 2018, down from 44 in Q4 2017.
- Funds reported $20M of vTv Therapeutics stock for Q1 2018, down 9.3% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q1 2018 and 8 closed out, a net change of -3 holders.
- The largest vTv Therapeutics buyer in Q1 2018 was GMT Capital, an estimated $5.75M added.
- The largest vTv Therapeutics seller in Q1 2018 was Ameriprise, an estimated $1.04M sold.
Based on aggregated 13F filings for Q1 2018.